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Background. There are no reliable signs or symptoms that differentiate Mycoplasma pneumoniae (Mp) infection in community-
acquired pneumonia (CAP) from other etiologies. Additionally, current diagnostic tests do not reliably distinguish between Mp 
infection and carriage. We previously determined that the measurement of Mp-specific immunoglobulin M antibody-secreting cells 
(ASCs) by enzyme-linked immunospot assay allowed for differentiation between infection and carriage. Using this new diagnostic 
test, we aimed to identify clinical and laboratory features associated with Mp infection.
Methods. This is a prospective cohort study of children, 3–18 years of age, with CAP from 2016 to 2017. Clinical features and 
biomarkers were compared between Mp-positive and -negative groups by Mann-Whitney U test or Fisher exact test, as appropriate. 
Area under the receiver operating characteristic curve (AUC) differences and optimal thresholds were determined by using the 
DeLong test and Youden J statistic, respectively.
Results. Of 63 CAP patients, 29 were Mp-positive (46%). Mp positivity was statistically associated with older age (median, 8.6 
vs 4.7 years), no underlying disease, family with respiratory symptoms, prior antibiotic treatment, prolonged prodromal respira-
tory symptoms and fever, and extrapulmonary (skin) manifestations. Lower levels of C-reactive protein, white blood cell count, 
absolute neutrophil count, and procalcitonin (PCT), specifically PCT <0.25 μg/L, were statistically associated with Mp infection. 
A combination of age >5 years (AUC = 0.77), prodromal fever and respiratory symptoms >6 days (AUC = 0.79), and PCT <0.25 μg/L 
(AUC = 0.81) improved diagnostic performance (AUC = 0.90) (P = .05).
Conclusions. A combination of clinical features and biomarkers may aid physicians in identifying patients at high risk for 
Mp CAP.
Keywords. antibiotics; C-reactive protein; diagnosis; procalcitonin; treatment.
Mycoplasma pneumoniae (Mp) is a common bacterial cause 
of community-acquired pneumonia (CAP) in children [1, 2]. 
There are substantial challenges in differentiating infection from 
carriage for Mp [3, 4]. Current diagnostic tests, including poly-
merase chain reaction (PCR) of upper respiratory tract (URT) 
specimens or serology, do not reliably differentiate between Mp 
infection and carriage [4]. Therefore it is not surprising that pre-
vious studies found no signs or symptoms to differentiate Mp in-
fection in CAP from other etiology [5, 6], potentially because Mp 
detection was misclassified as infection when in fact it was car-
riage. Mp carriage is estimated to occur in up to 56% of healthy 
children [4, 5]. Mp infection is generally mild and self-limiting, 
and patients with Mp CAP are mostly managed in primary 
care [7]. The lack of a cell wall makes Mp naturally resistant to 
first-line empirical β-lactam antibiotics for CAP [5]. Empirical 
macrolide treatment is extensively used to cover potential Mp 
infection, which has led to the emergence of macrolide-resistant 
Mp and a parallel rise in macrolide resistance in other respira-
tory pathogens [8]. Therefore, with the challenges in diagnostic 
testing for Mp and its limited use in the primary care setting, it is 
essential to determine clinical features and biomarkers to aid in 
the diagnosis of Mp infection in children with CAP.
We recently demonstrated in a prospective cohort study of 
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blood immunoglobulin M (IgM) antibody-secreting cells 
(ASCs) by enzyme-linked immunospot (ELISpot) assay im-
proves diagnosis of Mp infection in CAP [9]. This test differen-
tiated between Mp infection and carriage. Using this dataset, we 
here aimed to identify clinical features and biomarkers associ-
ated with Mp CAP, in which infection may be more accurately 
identified with the measurement of Mp-specific IgM ASCs.
METHODS
Patients
Patients were enrolled between 1 May 2016 and 30 April 2017, at 
University Children’s Hospital Zurich [9]. CAP was clinically de-
fined as the presence of fever >38.5°C and tachypnea according 
to the British Thoracic Society (BTS) guidelines [2]. Eligible par-
ticipants were inpatients or outpatients aged 3–18 years. CAP pa-
tients <3 years of age were excluded to reduce the probability of 
viral infection, as it is highest in this age group [10–13]. Patients 
with hospital-acquired pneumonia, cystic fibrosis, or other 
chronic lung disorders (excluding asthma), or known primary or 
secondary immunodeficiencies, were excluded. The local ethics 
committee approved the protocol for this study (number 2016-
00148). Written informed consent was obtained from all parents 
and children ≥14 years of age.
Specimen Collection and Diagnostic Testing
All enrolled patients were investigated for Mp in pharyngeal swab sam-
ples by specific real-time PCR [9, 14]. If additional consent was given, 
blood samples were collected for separation of peripheral blood mon-
onuclear cells (PBMCs) and serum [9]. Serum was stored at −80°C. As 
detailed elsewhere [9], only CAP patients were included in this study if 
fresh (isolated ≤4 hours) PBMCs were available to avoid poor ELISpot 
assay performance, and tested for the presence of Mp IgM ASCs. 
A CAP patient with a positive Mp IgM ASC ELISpot assay result was 
considered to have CAP caused by Mp (Mp positive). If Mp IgM ASCs 
were not detected, the patient was considered to have CAP caused by 
another etiology (Mp negative). We additionally investigated the fre-
quency of Mp by PCR from pharyngeal swabs among household con-
tacts available for sampling at presentation of index patients.
After study closure, pharyngeal swab samples kept at −80°C were 
additionally tested for Streptococcus pneumoniae (Sp) by real-time 
PCR [15], knowing that detection of Sp in the URT is likely colo-
nization and not infection [16]. In fact, coinfection with Sp and Mp 
is uncommon, whereas co-colonization may be more common [4, 
12]. Another 23 viral and bacterial respiratory pathogens were tested 
using the ePlex respiratory pathogen panel (GenMark Diagnostics, 
Carlsbad, California), as previously described [17]. In addition, Mp 
serology was performed (Virion\Serion, Würzburg, Germany). The 
study test results were not available to treating clinicians.
Clinical Data
Demographic, epidemiological, and clinical data were sys-
tematically collected using a standardized questionnaire. Full 
recovery was assessed until 6  months after enrollment. Chest 
radiographs were ordered for clinical reasons and therefore 
were not available in 3 (5%) patients. Chest radiographs were 
assessed by a radiologist during routine clinical care. These ra-
diological findings and the corresponding images were retro-
spectively reviewed by 2 of the authors, who were blinded to 
clinical information, using criteria for radiographic pneumonia 
[18, 19].
Laboratory Data
Blood cell count and C-reactive protein (CRP) analysis was 
performed as part of routine clinical care. Procalcitonin (PCT) 
testing was performed retrospectively in a batched analysis and 
results were not available to treating physicians. PCT levels 
were measured using a sensitive assay with a detection limit of 
0.007 ng/mL (B·R·A·H·M·S PCT sensitive KRYPTOR, Thermo-
Scientific, Berlin, Germany) [20].
Statistical Analysis
The nonparametric Mann-Whitney U test was used to com-
pare continuous variables and the Fisher exact test to com-
pare proportions between Mp-positive and Mp-negative 
groups. We calculated the area under the receiver operating 
characteristic (ROC) curve (AUC) of clinical features and 
biomarkers in differentiating between groups determined by 
Mp IgM ASC ELISpot assay (reference standard). We con-
sidered AUC ≥ 0.75 as adequate discrimination [21]. AUC 
differences were calculated using the DeLong test. Missing 
values were removed (ignored by roc.formula [22]). The best 
biomarker threshold was defined as the optimal cutoff that 
maximized the distance to the identity (diagonal) line in the 
ROC curve according to Youden J statistic. All reported P 
values are 2-tailed with statistical significance defined as P 
value <.05. Data were analyzed using the R software environ-
ment, version 3.6.0 [22].
RESULTS
Study Population
During the 12-month study period, 152 CAP patients were en-
rolled and Mp DNA was detected by PCR in 44 (29%) partici-
pants. Of the enrolled population, 63 (41%) CAP patients met 
the criteria of having fresh PBMCs available to undergo diag-
nostic testing with the Mp IgM ASC ELISpot assay and were 
included in this study. Of these, 29 (46%) were Mp-positive, de-
termined by detection of Mp IgM ASCs. As detailed elsewhere 
[9], all 29 Mp IgM ASC-positive patients were also Mp PCR 
positive and IgM positive. However, Mp PCR was also positive 
in 3 (5%) patients who were Mp IgM ASC and IgM negative, 
and Mp IgM was found in another 3 (5%) patients who were Mp 
IgM ASC and PCR negative. Chest radiographs were performed 
in 60 of 63 (95%) included CAP patients, whereof 59 (98%) met 
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Table 1. Demographic, Epidemiological, and Clinical Characteristics of Mycoplasma pneumoniae–Positive Community-acquired Pneumonia (CAP) 




Mp-Negative CAPa  
(n = 34) OR  (95% CI) P Value
Demographic characteristics     
 Age, yb, median (IQR) 8.6 (6.3–11.0) 4.7 (3.9–6.2) … < .01
 Sex, male 16 (55) 23 (68) 0.6 (.2–1.9) .44
 Season at enrollment     
  Spring (March–May) 5 (17) 6 (18) 1.0 (.2–4.4) 1.00
  Summer (June–August) 9 (31) 4 (12) 3.3 (.8–16.8) .07
  Autumn (September–November) 9 (31) 8 (23) 1.5 (.4–5.2) .58
  Winter (December–February) 6 (21) 16 (47) 0.3 (.1–1.0) .04
 Daycare or preschool attendance 29 (100) 34 (100) NA 1.00
 Immunizationsc 21/23 (91) 31/32 (97) 0.3 (.0–7.0) .57
 Underlying diseased 1 (3) 9 (26) 0.1 (.0–.8) .02
  Asthma or history of wheezing 1 1 …  
  Cardiovascular 0 0 …  
  Gastrointestinal 0 2 …  
  Neurological 0 2 …  
  Other 0 4 …  
 Family with RTI 17 (59) 10 (29) 3.3 (1.1–11.0) .02
  Mothers 14 4 …  
  Fathers 6 1 …  
  Siblings 17 7 …  
 Family members with Mp detection in URT 17/47 (36) 2/37 (5) 9.7 (2.0–93.2) < .01
  Mothers 7/20 (35) 2/26 (8) 6.2 (1.0–69.7) .03
  Fathers 1/13 (8) 0/10 (0) NA 1.00
  Siblings 9/14 (64) 0/1 (0) NA .40
  Symptomatic (RTI) 10/17 (59) 1/2 (50) 1.4 (.0–123.1) 1.00
  Asymptomatic (carrier) 7/17 (41)e 1/2 (50)e 0.7 (.0–62.7) 1.00
 Prior antibiotic treatment 13 (45) 5 (15) 4.6 (1.3–19.6) .01
Clinical presentation     
 Prodrome     
  RTI symptoms, d, median (IQR) 9.0 (6.0–10.0) 4.0 (3.0–7.0) … < .01
  Fever, d, median (IQR) 8.0 (6.0–10.0) 4.0 (3.3–6.0) … < .01
  Fever >2 df 26 (90) 28 (82) 1.8 (.3–12.5) .49
 Fever, °C, at presentation, median (IQR) 39.1 (39.0–39.7) 39.2 (39.0–39.5) … .89
 RTI symptoms and signs at presentationg     
  Runny nose 7 (24) 14 (41) 0.5 (.1–1.5) .19
  Sore throat 4 (14) 4 (12) 1.2 (.2–7.1) 1.00
  Cough 27 (93) 30 (88) 1.8 (.2–21.2) .68
  Chest pain 3 (10) 7 (21) 0.5 (.1–2.2) .32
  Wheezing 0 (0) 1 (3) NA 1.00
  Abnormal auscultatory findings 19 (66) 24 (71) 0.8 (.2–2.6) .79
  Oxygen saturation < 93% 5 (17) 8 (24) 0.7 (.2–2.8) .76
Radiographic findings     
 Pulmonary infiltrate in chest radiographh 28/28 (100) 31/32 (97) NA 1.00
 Consolidation 18 (64) 25 (78) 0.5 (.1–1.8) .26
  Single lobar infiltrate 13 16 …  
  Multilobar infiltrates 5 9 …  
  Multilobar infiltrates (unilateral) 1 3 …  
  Multilobar infiltrates (bilateral) 4 6 …  
 Interstitial 10 (36) 6 (19) 2.4 (.6–9.5) .16
  Reticular 10 6 …  
  Nodular 0 0 …  
 Pleural effusion 4 (14) 7 (22) 0.6 (.1–2.7) .52
Severity of illness
 Hospitalization 10 (34) 19 (56) 0.4 (.1–1.3) .13
  LOS, d, median (IQR) 4.5 (3.3–7.0) 2.5 (2.0–5.8) … .31
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Clinical Characteristics
The median age of Mp-positive patients (8.6 [interquartile 
range {IQR}, 6.3–11.0] years) was higher compared to Mp-
negative patients with CAP (4.7 [IQR, 3.9–6.2] years) (P < .01; 
Table 1). Mp-positive CAP was more likely than Mp-negative 
CAP to present during summer (odds ratio [OR], 3.3 [95% 
confidence interval {CI}, .8–16.8]). Underlying disease was 
less common among Mp-positive than Mp-negative patients 
(3% vs 26%; P = .02). Mp-positive patients were significantly 
more likely than Mp-negative patients to have received prior 
antibiotic treatment (OR, 4.6 [95% CI, 1.3–19.6]), whereas 
amoxicillin with or without clavulanic acid was the most fre-
quent agent in both groups (Mp-positive, n = 9/13 [69%] vs 
Mp-negative, n  =  4/5 [80%]). A  positive family history for 
respiratory tract infection (RTI) was reported in 17 (59%) 
Mp-positive compared to 10 (29%) Mp-negative patients 
(OR, 3.3 [95% CI, 1.1–11.0]; P  =  .02). Household contacts 
of Mp-positive index patients were significantly more likely 
to have Mp detected in the URT than those of Mp-negative 
index patients (OR, 9.7 [95% CI, 2.0–93.2]; P <  .01). Only 2 
family members (5%, both mothers) of Mp-negative index 
patients were PCR positive, of which 1 had RTI symptoms. 
Among household contacts of Mp-positive index patients, Mp 
was detected in the URT of 9 siblings (64%), 7 mothers (35%), 
and 1 father (8%). Most of them reported having RTI symp-
toms (59%), but 6 siblings and 1 mother were asymptomatic 
carriers.
The duration of RTI symptoms and fever prior to CAP diag-
nosis was longer in Mp-positive (median, 9.0 [IQR, 6.0–10.0] 
days) than Mp-negative patients (4.0 [IQR, 3.0–7.0] days; 
P < .01). No other symptoms and signs were statistically dif-
ferent between groups. Mp-positive patients were no different 
than Mp-negative patients to have consolidation, interstitial 
infiltrates, or pleural effusion. Extrapulmonary manifestations 
were only observed in Mp-positive children with CAP (31% 
vs 0%; P < .01) and included dermatological and neurological 
disorders (Table 1). After inclusion, 9 (31%) of Mp-positive 
patients were not treated with an antibiotic in vitro active 
against Mp.
Hospitalization rates and length of hospital stay were sim-
ilar between the 2 groups. Detailed characteristics for hospi-
talized and ambulatory Mp-positive and Mp-negative patients 
are shown in Supplementary Tables 1 and 2. Among hospital-
ized patients, Mp-positive patients were more likely to have 
oxygen demand, extrapulmonary manifestations, and poor out-




Mp-Negative CAPa  
(n = 34) OR  (95% CI) P Value
 Extrapulmonary manifestation 9 (31)i 0 (0) NA < .01
  Dermatological 8 … …  
  Neurological 1 … …  
Treatment     
 Antibiotics after enrollment 27 (93)j 31 (91)j 1.3 (.1–16.7) 1.00
  Amoxicillin ± clavulanic acid 13 (45) 29 (85) 0.1 (.0–.5) < .01
  Clarithromycin 10 (34) 1 (3) 16.7 (2.1–772.7) < .01
  Doxycycline 10 (34) 1 (3) 16.7 (2.1–772.7) < .01
  Other 1 (3) 2 (6) 0.6 (.0–11.6) 1.00
Outcome     
 Full recovery 26 (90)k 34 (100) NA .09
  Respiratory sequelae 2 … …  
  Dermatological sequelae 1 … …  
Data are presented as no. or no. (%) unless otherwise indicated. Differences between groups were determined by the Mann-Whitney U test (medians) and Fisher exact test (proportions). P 
values <.05 are indicated in bold.
Abbreviations: CAP, community-acquired pneumonia; CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; LOS, length of hospital stay; Mp, Mycoplasma pneumoniae; 
NA, not available; OR, odds ratio; RTI, respiratory tract infection; URT, upper respiratory tract.
aDefined according to the Mp-specific immunoglobulin M (IgM) antibody-secreting cell (ASC) enzyme-linked immunospot assay results [9].
bOnly patients between 3 and 18 years of age were enrolled (inclusion criteria) [9].
cPer the national immunization schedule in Switzerland.
dChronic lung disorders (excluding asthma) were part of the exclusion criteria [9].
eAsymptomatic carriers: Mp-positive CAP family members: 6 siblings, 1 mother; Mp-negative CAP family members: 1 mother.
fAccording to the prediction rule for risk of Mp infection in children with CAP by Fischer et al [23].
gInclusion criteria were clinical diagnosis of CAP with fever >38.5°C and tachypnea according to the British Thoracic Society guidelines [2].
hRadiographic evidence of pneumonia was not part of inclusion criteria, but routinely performed in 60 of 63 (95%) included CAP patients; 98% (59/60) met the criteria for radiological pneu-
monia [18, 19].
iDermatological (n = 8) [32]: Mp-induced rash and mucositis (n = 3), urticaria (n = 2), and maculopapular skin eruptions (n = 3); neurological (n = 1): aseptic meningitis.
jAntibiotic treatment with ≥1 agent: Mp-positive CAP: amoxicillin with or without clavulanic acid + clarithromycin (n = 4), amoxicillin with or without clavulanic acid + doxycycline (n = 3); 
Mp-negative CAP: amoxicillin + clarithromycin (n = 1), amoxicillin with or without clavulanic acid + ceftazidime (n = 1). Mp-positive CAP not treated with an antibiotic in vitro active against 
Mp: 9 (31%); all of them fully recovered.
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in 3 (10%) hospitalized Mp-positive patients (ie, bronchiolitis 
obliterans, exertional dyspnea, and postinflammatory pigmen-
tary alteration). All Mp-negative patients fully recovered.
Laboratory Findings
Hematological assessment together with PCT and CRP anal-
ysis for Mp-positive and Mp-negative CAP patients is shown in 
Table 2. Mp-positive CAP patients had lower white blood cell 
(WBC) count, absolute neutrophil count (ANC), PCT, and CRP 
values than Mp-negative patients (Figure 1).
Detection of Pathogens
Differences in clinical features and biomarkers may be at-
tributed to another pathogen causing a subset of infections. 
Therefore, pharyngeal swab samples were tested in this study 
for other pathogens. Two or more pathogens were found in 
the URT of 20 (69%) Mp-positive and 13 (38%) Mp-negative 
patients (Table 3). Sp was equally detected in both cohorts in 
>60%. Exclusively found in Mp-negative patients was respira-
tory syncytial virus (RSV; n = 8 [24%]; P < .01), influenza virus 
(n = 2), parainfluenza virus (n = 2), and coronavirus (n = 1). No 
virus was statistically associated with Mp positivity. Rhinovirus, 
adenovirus, and bocavirus were equally detected in both co-
horts. Thus, we also compared clinical features and biomarkers 
of Mp-positive patients against the following subgroups of Mp-
negative patients (n = 34): first, positive for RSV (n = 8, as it is 
the only virus for which detection in the URT has a high pre-
dictive value for CAP etiology [16]); second, positive for other 
Table 2. Laboratory Findings of Mycoplasma pneumoniae–Positive Community-acquired Pneumonia (CAP) Versus M.  pneumoniae–Negative CAP in 
Children
Laboratory Finding Mp-Positive CAP (n = 29) Mp-Negative CAP (n = 34) OR  (95% CI) P Value
Blood cell count    
 WBC count, ×109 cells/L, median (IQR) 8.97 (6.91–11.80) 12.30 (9.11–20.48) … .01
  Abnormala 5/21 (24) 13/26 (50) 0.3 (.1–1.3) .08
  Leukocytosis 4 12 …  
  Leukopenia 1 1 …  
 ANC, ×109 cells/L, median (IQR) 6.63 (4.21–8.70) 10.00 (6.17–17.29) … .02
  Abnormala 7/21 (33) 14/25 (56) 0.4 (.1–1.5) .15
  Neutrophilia 7 14 …  
  Neutropenia 0 0 …  
 Lymphocyte count, ×109 cells/L, median (IQR) 1.45 (1.16–2.29) 1.77 (1.19–2.58) … .52
  Abnormala 8/21 (38) 7/24 (29) 1.5 (.4–6.2) .55
  Lymphocytosis 0 0 …  
  Lymphopenia 8 7 …  
 Monocyte count, ×109 cells/L, median (IQR) 0.71 (0.47–0.96) 0.89 (0.63–1.11) … .21
  Abnormala 2/21 (10) 1/24 (4) 2.4 (.1–148.8) .59
  Monocytosis 2 1 …  
  Absolute monocytopenia 0 0 …  
 Eosinophil count, ×109 cells/L, median (IQR) 0.13 (0.04–0.22) 0.01 (0.00–0.13) … .05
  Abnormala 3/20 (15) 10/24 (42) 0.3 (.0–1.3) .09
  Eosinophilia 1 2 …  
  Absolute eosinopenia 2 8 …  
 Basophil count, ×109 cells/L, median (IQR) 0.05 (0.02–0.07) 0.04 (0.02–0.07) … .98
  Abnormala 0/20 (0) 0/24 (0) NA 1.00
 Anemiaa 2/21 (10) 8/26 (31) 0.2 (.0–1.5) .15
 Platelet count, ×109 cells/L, median (IQR) 315 (289–378) 310 (252–356) … .27
  Abnormala 6/21 (29) 4/25 (16) 2.1 (.4–11.8) .48
  Thrombocytopenia 5 3 …  
  Thrombocytosis 1 1 …  
Chemistry     
 PCT, μg/L, median (IQR) 0.06 (0.04–0.14) 0.28 (0.12–1.75) … < .01
 CRP, mg/L, median (IQR) 16 (8–36) 72 (24–170) … < .01
 CRP/PCT ratio, mg/μg, median (IQR) 200 (84–452) 104 (39–320) … .27
 CRP/PCT ratio >400 mg/μgb 9 (31) 7 (21) 1.7 (.5–6.5) .39
Data are presented as no. or no. (%) unless otherwise indicated. Differences between groups were determined by the Mann-Whitney U test (medians) and Fisher exact test (proportions).  
P values <.05 are indicated in bold.
Abbreviations: ANC, absolute neutrophil count; CAP, community-acquired pneumonia; CI, confidence interval; CRP, C-reactive protein; IQR, interquartile range; Mp, Mycoplasma pneumoniae; 
NA, not available; OR, odds ratio; PCT, procalcitonin; WBC, white blood cell. 
aAge-specific reference values for hematology were defined as previously described [46].
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viruses than RSV (n  =  7, being aware that URT detection of 
other pathogens than RSV may not be related to pneumonia 
[3]); and third, negative for viruses (n = 19, in which Sp was 
detected in 14 [74%] in the URT and additionally in 2 of 2 in 
pleural aspirate during routine clinical care). However, although 
numbers were again smaller for this subanalysis, Mp-positive 
CAP was also compared to subgroups of Mp-negative CAP sta-
tistically associated with older age, prolonged prodromal respi-
ratory symptoms, and low levels of PCT (Supplementary Figure 
1 and Supplementary Table 3).
ROC Analysis and Performance Curves
ROC analysis was performed for clinical features and bio-
markers that were associated with Mp-positive CAP. The ROC 
curves showed good discriminative ability (AUC ≥ 0.75) in 
differentiating groups for age (AUC = 0.77), duration of prod-
romal symptoms (AUC = 0.79), PCT (AUC = 0.81), and CRP 
(AUC = 0.76) (Figure 2A and 2B).
The best clinical threshold to discriminate Mp-positive from 
Mp-negative patients was age 5 years and prodromal fever and 
RTI symptom duration of 6  days (Table 4). The optimal bio-
marker thresholds were 0.25 μg/L for PCT, 50 mg/L for CRP, 
18 × 109/L for WBC count, and 8 × 109/L for ANC. For assess-
ment of Mp-positive CAP, the positive likelihood ratios were 
highest for age >5 years (2.2 [95% CI, 1.4–3.3]), duration of fever 
>6 days (3.1 [95% CI, 1.6–5.9]), and RTI symptoms >6 days (2.5 
[95% CI, 1.4–4.3]), as well as for PCT <0.25 μg/L (2.2 [95% CI, 
1.5–3.2]) and CRP <50 mg/L (2.3 [95% CI, 1.4–3.5]) (Table 4). 
Using a PCT cutoff of <0.25 μg/L, only 1 (3%) Mp-positive pa-
tient had a PCT concentration above this cutoff compared with 
19 (56%) Mp-negative patients (P < .01). The Mp-positive CAP 
patient with the high PCT level (ie, 0.55 μg/L) developed bron-
chiolitis obliterans and dermatological manifestations.
The combination of clinical features and biomarkers was 
more effective in the diagnosis of Mp CAP compared with 
either clinical features or biomarkers alone (Figure 2C). 
Improved diagnostic performance was reached by combining 
clinical features (ie, age with duration of prodromal symptoms: 
AUC = 0.82 [95% CI, .7–.9]) together with PCT (AUC = 0.90 
[95% CI, .8–1.0]) (P = .05; Table 4).
DISCUSSION
We evaluated clinical features and biomarkers to diagnose Mp 
infection within a well-defined cohort of ambulatory and hospi-
talized children with CAP, in which Mp infection was diagnosed 
with the Mp IgM ASC ELISpot assay that allows for the differ-
entiation between Mp infection and carriage [9]. Diagnosing 
Mp as the cause of CAP at an early stage is important to avoid 
ineffective first-line empirical β-lactam antibiotics and to eval-
uate targeted treatment against Mp in severe cases [2].
Several scores, ratios, algorithms, and prediction rules have 
been reported to diagnose Mp infection on the basis of clin-
ical features [5, 7, 23, 24]. However, previous studies found 
no reliable signs or symptoms to differentiate Mp infection in 
CAP from other etiology [5, 6], potentially because Mp infec-
tion was misclassified as infection when it was carriage. We 
recently demonstrated that the Mp IgM ASC ELISpot assay 
differentiates Mp infection from carriage [9]: While Mp DNA 
and/or IgM were also detected in 48% and 29% healthy control 
children (n = 21), all were tested negative by the Mp IgM ASC 
ELISpot assay [9]. Notably, the high Mp detection rate in CAP 
patients (46%) in this study may be related to the inclusion 
age of 3–18  years, in which Mp is most frequently detected 
[1, 2], and the coinciding Mp epidemic in Europe during the 
study period [25–28]. Prevalence estimates are important for 
translation of diagnostic study findings into clinical practice. 
Figure 1. Biomarker test results of Mycoplasma pneumoniae–positive community-acquired pneumonia (CAP) vs M. pneumoniae–negative CAP in children: procalcitonin 
(A), C-reactive protein (B), white blood cell count (C), absolute neutrophil count (D). The P value is indicated in the graphs (Mann-Whitney U test). Abbreviations: ANC, absolute 
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When taking the Bayes theorem into account, the posttest 
probability of disease presence will be higher given a higher 
pretest probability or prevalence [29–31]. For proper imple-
mentation of a new diagnostic test into clinical practice, it is 
therefore necessary that the test will be assessed in the context 
of all the other diagnostic information that is available at the 
time point of testing.
We were able to corroborate previous study findings in that 
Mp-positive CAP manifests predominantly in school-aged 
children >5 years [1, 12, 23] and children present with prod-
romal fever and respiratory symptoms of >6 days [1], signifi-
cantly longer compared with CAP caused by other etiology. 
Other symptoms and signs, as well as radiographic findings, did 
not differentiate Mp-positive from Mp-negative CAP [1, 5, 6]. 
Table 3. Pathogen Detection in Upper Respiratory Tract of Mycoplasma pneumoniae–Positive Community-acquired Pneumonia (CAP) Versus 
M. pneumoniae–Negative CAP in Children
Pathogen Mp-Positive CAP (n = 29) Mp-Negative CAP (n = 34) OR (95% CI) P Value
Pathogen     
 Any pathogen 29 (100) 29 (85) NA .06
 ≥2 pathogens 20 (69) 13 (38) 3.5 (1.1–11.7) .02
 ≥3 pathogens 7 (24) 5 (15) 1.8 (.4–8.4) .52
Bacteria     
 Any bacteria 29 (100) 26 (76) NA < .01
 Mp 29 (100) 3 (9) NA < .01
 Sp 18 (62) 26 (76)a 0.5 (.1–1.7) .27
 Chlamydophila pneumoniae 0 (0) 1 (3) NA 1.00
 Legionella pneumophila 0 (0) 0 (0) NA 1.00
 Bordetella pertussis 0 (0) 0 (0) NA 1.00
Viruses     
 Any virus 9 (32) 15 (45) 0.6 (.2–1.8) .31
 RSV 0 (0) 8 (24)b NA < .01
  A … 2 …  
  B … 3 …  
 Influenza virus 0 (0) 2 (6) NA .50
  A … 2 …  
  A(H1) … 0 …  
  A(2009 H1N1) … 0 …  
  A(H3) … 1 …  
  B … 0 …  
 Parainfluenza virus 0 (0) 2 (6) NA .50
  1 … 0 …  
  2 … 2 …  
  3 … 0 …  
  4 … 0 …  
 Human rhinovirus/enterovirusc 3 (11) 4 (12) 0.9 (.1–5.7) 1.00
 Adenovirus 5 (18) 3 (9) 2.1 (.4–15.3) .45
 Human metapneumovirus 0 (0) 0 (0) NA 1.00
 Coronavirus 0 (0) 1 (3) NA 1.00
  229E … 0 …  
  HKU1 … 0 …  
  NL63 … 0 …  
  OC43 … 1 …  
  MERS coronavirus … 0 …  
 Human bocavirus 1 (4) 1 (3) 1.2 (.0–95.8) 1.00
Data are presented as no. or no. (%). Differences between proportions were determined by the Fisher exact test. P values <.05 are indicated in bold. Pharyngeal samples were tested in all 
patients by real-time polymerase chain reaction (PCR) for Mp [14] and Sp [15], and for other bacterial and viral pathogens by the ePlex respiratory panel [17] in 28 of 29 Mp-positive CAP and 
33 of 34 Mp-negative CAP patients with residual respiratory samples. Blood cultures were performed in 14 (48%) Mp-positive CAP and 20 (59%) Mp-negative CAP patients during routine 
clinical care and all were negative. Routine PCR testing for Mp [14] as part of clinical care was positive in 8 of 8 Mp-positive CAP and 0 of 11 Mp-negative CAP patients.
Abbreviations: CAP, community-acquired pneumonia; CI, confidence interval; MERS, Middle East respiratory syndrome; Mp, Mycoplasma pneumoniae; NA, not available; OR, odds ratio; 
RSV, respiratory syncytial virus; Sp, Streptococcus pneumoniae.
aTwo patients had Sp detected in both upper respiratory tract (URT) and pleural fluid samples (pleural puncture performed during routine clinical care). They had no other pathogens detected 
in the URT apart from Sp.
bRSV was additionally detected in nasopharyngeal samples of 3 patients by rapid antigen detection test (Sofia, Quidel, San Diego, California) during routine clinical care.
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Extrapulmonary manifestations, predominantly skin disorders, 
were statistically associated with Mp-positive CAP in this study. 
Its presence significantly increases the probability of underlying 
Mp infection [32]. This may be also true for the presence of RTI 
within families of Mp-positive CAP patients. Our observation 
of frequent RTI symptoms and Mp detection in members of 
those families supports previous data about Mp spread among 
persons in close contact and family transmission of Mp [33–36].
Mp infection is mild and self-limiting in most cases, and 
manifests predominantly in previously healthy children [5]. 
In our study, one-third of Mp-positive CAP patients were not 
treated with an antibiotic in vitro active against Mp, but all of 
these children fully recovered. The BTS guidelines advise that 
macrolide antibiotics may be added at any age in case of very 
severe disease or if there is no response to first-line empirical 
treatment [2]. Prior antibiotic treatment was associated with 
Mp CAP and included treatment with β-lactam antibiotics in 
most cases. This supports that in patients that do not respond to 
β-lactam antibiotics, Mp CAP should be considered [2, 7]. We 
did not find statistical differences in fever duration following 
CAP diagnosis, hospital length of stay, or recovery at follow-up 
between Mp-positive patients who did and did not receive anti-
biotics against Mp (data not shown). These findings support 
the need for future interventional studies assessing the effect of 
antibiotics for Mp CAP [1, 9, 37, 38].
Our study demonstrated that in Mp-positive CAP biomarker 
levels of PCT, CRP, WBC count, and ANC were statistically lower 
compared with Mp-negative CAP. Despite limited numbers, this 
Figure 2. Receiver operating characteristic (ROC) curve of sensitivity vs specificity for clinical features (A), biomarkers (B), and a combination of both (C). Area under the 
ROC curve (AUC) differences (DeLong test): A and B, No significant AUC differences. C, *P = .37 (age vs combination of clinical features); **P = .05 (combination of clinical 
features vs combination of clinical features plus procalcitonin). Abbreviations: ANC, absolute neutrophil count; CRP, C-reactive protein; PCT, procalcitonin; RTI, respiratory 
tract infection; WBC, white blood cell.
Table 4. Best Thresholds With Diagnostic Accuracy for Mycoplasma pneumoniae–Positive Community-acquired Pneumonia (CAP) Versus M. pneumoniae–
Negative CAP in Children
Parameter Threshold Sensitivity (95% CI) Specificity (95% CI)







 Age, y >5 0.90 (.74–.96) 0.59 (.42–.74) 2.18 (1.43–3.31) 0.18 (.06–.53) 0.77 (.64–.89)
 Fever, d >6 0.72 (.54–.85) 0.76 (.60–.88) 3.08 (1.61–5.87) 0.36 (.19–.67) 0.72 (.59–.86)
 RTI symptoms, d >6 0.72 (.54–.85) 0.71 (.54–.83) 2.46 (1.40–4.34) 0.39 (.21–.73) 0.79 (.68–.91)
Biomarkers
 PCT, μg/L <0.25 0.97 (.83–.99) 0.56 (.39–.71) 2.19 (1.49–3.21) 0.06 (.01–.43) 0.81 (.70–.92)
 CRP, mg/L <50 0.86 (.69–.95) 0.62 (.45–.76) 2.25 (1.44–3.54) 0.22 (.09–.58) 0.76 (.63–.88)
 WBC count, ×109 cells/L <18.00 0.95 (.77–.99) 0.38 (.22–.57) 1.55 (1.13–2.13) 0.12 (.02–.89) 0.71 (.56–.86)
 ANC, ×109 cells/L <8.00 0.67 (.45–.83) 0.60 (.41–.77) 1.67 (.94–2.94) 0.56 (.28–1.10) 0.71 (.56–.86)
Combination
 Age + fever + RTI symptoms As defined above 1.00 (.88–1.00) 0.44 (.29–.61) 1.79 (1.33–2.41) NA 0.82 (.71–.92)
 Age + fever + RTI symptoms + PCT As defined above 1.00 (.88–1.00) 0.32 (.19–.49) 1.48 (1.17–1.87) NA 0.90 (.83–.97)
The threshold is the optimal cutoff that maximizes the distance to the identity (diagonal) line in the receiver operating characteristic curve in Figure 2 according to the Youden J statistic using 
the “coords” function in R software environment (version 3.6.0) [22].
Abbreviations: ANC, absolute neutrophil count; AUC, area under the receiver operating characteristic curve; CI, confidence interval; CRP, C-reactive protein; LR, likelihood ratio; NA, not 
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was even true for PCT and CRP of Mp-positive CAP in compar-
ison to viral CAP (RSV) as a subgroup of Mp-negative CAP. 
Similar trends have been observed in previous CAP studies for 
CRP, WBC count, and ANC [23, 39–43], and recently for PCT 
with median levels from 0.05 to 0.19 μg/L in CAP considered to 
be caused by Mp [39–41, 44]. A study with conflicting results 
suggesting higher PCT levels associated with Mp may be ham-
pered by diagnostics [45]. A PCT cutoff of <0.25 μg/L reached 
the best discriminatory power in differentiating Mp-positive 
from Mp-negative children with CAP, which is supported by 
previous studies [39–41, 44]. Only 1 Mp-positive patient had a 
PCT level of 0.55 μg/L and was above this cutoff.
Our study has several limitations. First, though sampling 
was performed in a relevant population of clinical CAP [9], the 
study population is small and represents a convenience sample 
from an observational study, and we cannot rule out that unin-
tended selection occurred. However, even though the sample 
size is small for prediction, the scope of this study was to de-
scribe risk factors for Mp infection. Second, mild cases may not 
have been referred to our tertiary center. Third, the study en-
rolled children from 3 to 18 years of age to reduce the proba-
bility of viral infection [9]. However, younger children with Mp 
infection may have, more likely, other RTIs than CAP [43].
In conclusion, improved diagnostics helped to identify 
clinical features and biomarkers that may predict Mp CAP in 
children, such as age >5  years, no underlying disease, family 
with RTI, prior antibiotic treatment, prodromal respiratory 
symptoms and fever >6 days, as well as extrapulmonary (skin) 
manifestations. Biomarkers showed some differences between 
Mp-positive and Mp-negative patients in that Mp positivity was 
associated with low levels of CRP, WBC count, ANC, and PCT, 
particularly a PCT cutoff of <0.25 μg/L. However, the study size 
is small and even the best combinations of clinical features and 
biomarkers may not be reliable enough to be used as a diag-
nostic itself. Our data support that a combination of clinical 
features and biomarkers may help physicians in identifying pa-
tients at high risk for Mp CAP, which warrants further investi-
gations in a larger cohort of children with Mp infection.
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